Opioids do not improve quality of life or depression in OA patients

Opioids do not improve quality of life or depression in OA patients

New research presented at the 2019 ACR/ARP Annual Meeting suggests that opioids contribute no measurable benefit to the quality of life or depression for patients with osteoarthritis (OA).

Researchers also found only small benefits on pain and function after two to 12 weeks of treatment, and interestingly, strong opioids had consistently worse pain relief benefits and a greater risk of any safety-related outcome than weak opioids in this meta-analysis.

Osteoarthritis is a common joint disease that most often affects middle-age to elderly people. OA is a disease of the entire joint, involving the cartilage, joint lining, ligaments, and bone. OA is characterized by the breakdown of cartilage tissue, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining (called the synovium).

Opioids, long prescribed for chronic pain, have many safety concerns. The lack of information about opioids' efficacy for OA pain relief and no clear delineation between overall efficacy and safety between strong and weak opioids prompted the study.

Given the current controversy regarding the use of opioids in chronic pain, we wanted to delve deeper into the efficacy and safety profiles of oral opioid drugs in osteoarthritis patients. Temporal assessments can reveal peak periods of efficacy and can provide clinicians with a blueprint for optimal durations of treatment regimens.
Our study also provides an important update to the evidence body by evaluating patient reported outcomes of quality of life, depression and sleep that are relevant to clinicians and patients alike,"
Raveendhara R. Bannuru MD, PhD, FAGE

Bannuru is the director of the Center for Treatment Comparison and Integrative Analysis at Tufts Medical Center in Boston and the study's lead author.

The study included meta-analyses of pain and function at two, four, eight, and 12 weeks. It also analyzed relevant safety outcomes for all opioids, as well as strong versus weak opioids.

They searched MEDLINE and the Cochrane Database from inception to April 2019, and actively sought unpublished data. They included placebo-controlled, randomized controlled trials assessing the efficacy and/or safety of FDA-approved opioids in patients with knee and/or hip OA
Of the 23 randomized controlled trials included, there were 11,402 participants and 64 percent were female. The participants' mean age ranged from 54 to 67 years.

Their mean body-mass index (BMI) ranged from 28 to 34 kg/m2. All of the trials included in the study were of moderate quality, and potential attrition bias was the primary methodological concern.
Overall, the results showed that opioids demonstrated small, statistically significant benefits on pain at each time point.

Similarly, the researchers observed small, statistically significant effects on function at two, four, eight, and 12 weeks. Opioids had no impact on the quality of life or depression.

Strong opioids consistently had smaller benefits on pain than weak opioids, the study found. Though results of meta-regression exploring dose effects revealed a relevant relationship between opioid dosage, or morphine equivalency, and the magnitude of pain relief, participants receiving strong opioids were nearly twice as likely to discontinue due to adverse events than those receiving weak/intermediate opioids.

One possible reason is that many participants who received strong opioids were unable to achieve the optimal therapeutic dose as a result of attrition related to a lack of tolerability.

Strong opioids overall showed a consistently worse safety profile than weak opioids, particularly drug withdrawal symptoms and discontinuations due to adverse events.

"Strong opioids' underperformance was the study's most interesting finding, and likely due to the relationship between pain relief and tolerability of opioids based on dose," says Dr. Bannuru.

"We observed a relevant relationship between morphine dose equivalency and the magnitude of pain relief at the final follow-up. However, the relative risk of discontinuation due to adverse events among participants receiving strong opioids was nearly twice that of participants receiving weak opioids. These results suggest that many people who receive strong opioids may be unable to achieve the optimal therapeutic dose due to a lack of tolerability."

American College of Rheumatology

No comments